Uppsala, Sweden
Founded: 2000

Why It's Fierce: The company's products streamline laboratory testing, allowing researchers to generate more scientific information from smaller biological samples. Two-year-old Gyros has attracted an impressive list of former Pharmacia executives and backing from some of Europe's leading venture capitalists. The venture capital bust is bad in America. It's even worse in Europe. We think Gyros is a survivor.

What to look for in 2003: Gyros' strong finances and industry contacts will help the company gain traction this year as its competitors wither on the vine.



Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.